This retrospective study aims to evaluate the short-term efficacy and safety of brolucizumab every 6 weeks induction therapy for neovascular age-related macular degeneration (nAMD) cases. This study included 140 eyes from 140 patients (101 males and 39 females, with a mean age of 77.7 ± 8.7 years) with nAMD who received brolucizumab injections every 6 weeks as part of induction therapy across four participating centers between June 2020 and March 2024. Follow-up lasted for at least 20-24 weeks. Data collected included age, sex, history of nAMD treatment, best-corrected visual acuity (BCVA), central retinal thickness (CRT), presence or absence of exudation, and occurrence of intraocular inflammation (IOI). Sixty-one eyes had prior nAMD treatment. Mean BCVA (logMAR) was 0.40 ± 0.43 before brolucizumab therapy, improving to 0.38 ± 0.42, 0.33 ± 0.41, and 0.34 ± 0.44 after the first, second, and third injections, respectively. Significant improvements in BCVA were observed from the second injection onward (p <
0.05). CRT decreased significantly from baseline of 341.6 ± 151.0 to 219.1 ± 119.8, 204.0 ± 112.9, and 200.8 ± 96.0 after the first, second, and third injections, respectively (p <
1.0 × 10